

**Biotechnology company uses Pixel
Perfect to create Clinical Trial
Safety Reports from within Tableau**



Customer

Our customer is one of the largest bio-pharmaceutical companies in the world, with total assets worth over \$77 billion, and over 22,000 employees. The company focuses on molecular biology and biochemistry -providing healthcare based on recombinant DNA technology.

Reference available upon request.

Atopic dermatitis and eczema

Report Year	Trial code	Trial Title		Trial Number	EudraCTno.	Source
2017	LP0133-1180	A Phase 2a, Proof of Concept, testing twice daily applications of LEO 124249 ointment 30 mg/g in the treatment of chronic hand eczema		NCT02664805	N/A	Summary
		Active Substance LEO 124249	Product N/A	Formulation Ointment	Trial Phase 2a	Population adults
2017	LP0108-1082	An explorative trial evaluating the effect of LEO 32731 cream 20 mg/g in adults with mild to moderate atopic dermatitis (AD)		NCT02496546	2014-000519-15	Summary
		Active Substance LEO 32731	Product N/A	Formulation cream	Trial Phase 1	Population adults
2015	LP0083-1085	An explorative trial evaluating the effect of LEO 39652 cream 2.5 mg/g in adults with mild to moderate atopic dermatitis (AD)		NCT02219633	2014-000849-80	Summary/Report
		Active Substance LEO 39652	Product N/A	Formulation cream	Trial Phase 1	Population adults
2015	EXP-1092	A phase 1, multi-centre, randomised, vehicle-controlled, double-blinded, explorative clinical trial to evaluate a left-right design in adults with mild to moderate atopic dermatitis over a treatment period of three weeks		NCT02103725	2013-004301-66	Summary
		Active Substance N/A	Product N/A	Formulation cream	Trial Phase 1	Population adults
2016	EXP-1184	An explorative clinical trial to evaluate an intra patient comparison design of topical agents in adults with mild to moderate atopic dermatitis		NCT02376049	N/A	Summary
		Active Substance N/A	Product N/A	Formulation cream	Trial Phase 1	Population adults

Clinical Trial Safety

A report that records and monitors patient safety. The ultimate goal of the report is to collect safety data from multiple clinical trials that help detect safety signals, develop safety profiles of the drug, and protect patients from unnecessary risks.

A mandatory requirement, the report tracks serious adverse reaction and events of clinical trials – with the end goal of evolving medically relevant safety label information for products under development. When required at scale and minimal margin for error, these reports prove to be highly challenging and time consuming for healthcare providers to generate.

Now you can easily create pre-populated, perfectly formatted, print-ready reports, at scale and all at the click of a button from within your Tableau dashboard using Pixel Perfect.

[View Sample Report](#)

Highlights

In a bid to modernize their reporting, the pharma wanted to scale the use of Tableau within their organization. However, the pharma's advanced analytics and BI team still relied heavily on the use traditional reporting platforms when it came to generating Clinical Trial Safety Reports (which reports serious adverse events and reactions of clinical trials) as per the FDA guidelines and specifications.

With Pixel Perfect, the team was able to generate perfectly-formatted, print-ready PDF reports, at the click of a button from within Tableau dashboard. The product was deployed as 'On-Demand' service (hosted service run directly from the Tableau Server).The output reports adhered to all the business specifications, including:

- Business Logo
- Header and Footer
- TLF's (Tables, Listing & Figures)
- Dynamic parameters
- Multi report select and package functionality
- Custom cover page with bookmark

Pixel Perfect further helped simplify the pharma's regulatory reporting process -assisting them to retire their redundant BI platform (IBM Cognos) that was solely dedicated towards generating regulatory reports -helping the pharma save time, money, and effort.



pixel
perfect 

[Learn More](#)

[Request 1:1 Demo](#)